STOCK TITAN

Silexion Q3 2026 net loss narrows 24.2% to $2.53M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Silexion Therapeutics Corp (SLXN) reported a third-quarter net loss of $2.533 million, compared with $3.262 million a year earlier, and a nine-month net loss of $8.817 million versus $7.500 million. Cash and cash equivalents were $4.760 million and shareholders’ equity was $2.968 million as of September 30, 2026.

The company dosed the first patient in its Phase 2/3 SIL204 trial for locally advanced pancreatic cancer. The study combines SIL204 with chemotherapy versus chemotherapy alone, with an approximately 18-patient safety run-in followed by an approximately 166-patient randomized cohort. Silexion reported preclinical immune-sensitization and natural lipoprotein uptake findings; pharmacokinetic and biodistribution studies are ongoing. It disclosed substantial doubt about its ability to continue as a going concern and said it effected a 1-for-24 reverse share split on November 10, 2026.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointCompany-reported quarterly net loss decrease: 24.2%.

Negative

  • Major pointSilexion disclosed substantial doubt about its ability to continue as a going concern.
  • Moderate pointCompany-reported nine-month net loss increase: 17.3%.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Research and development expense, three months $1.286 million Three months ended September 30, 2026; $2.157 million in 2025; the company reported a 40.9% decrease.
General and administrative expense, three months $1.398 million Three months ended September 30, 2026; $1.135 million in 2025; the company reported a 27.3% increase.
Net loss, three months $2.533 million Three months ended September 30, 2026; $3.262 million in 2025; the company reported a 24.2% decrease.
Research and development expense, nine months $4.868 million Nine months ended September 30, 2026; $3.765 million in 2025; the company reported a 28.9% increase.
General and administrative expense, nine months $4.245 million Nine months ended September 30, 2026; $3.461 million in 2025; the company reported a 20.0% increase.
Net loss, nine months $8.817 million Nine months ended September 30, 2026; $7.500 million in 2025; the company reported a 17.3% increase.
Cash and cash equivalents $4.760 million As of September 30, 2026.
Shareholders’ equity $2.968 million As of September 30, 2026.
RNA interference (RNAi) technical
"pioneering RNA interference (RNAi) therapies"
A natural cellular process in which small RNA molecules shut down the production of a specific protein by blocking the instructions that make it, like flipping a precise light switch to silence one appliance without affecting others. For investors, RNA interference is important because it underpins a class of highly targeted therapies and research tools that can create new drugs, shorten development paths, and change the potential market and regulatory risks for companies working on gene-based treatments.
EUS-guided intratumoral delivery medical
"direct EUS-guided intratumoral delivery to the primary tumor"
KRAS mutation medical
"whose tumors harbor a confirmed KRAS mutation"
immune-sensitization signature medical
"a coordinated immune-sensitization signature across three immune pathways"
lipoprotein-mediated uptake technical
"a native lipoprotein-mediated uptake mechanism"
at-the-market facility financial
"continued sales under its at-the-market facility"
An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.
Research and development expense, three months $1.286 million Company-reported decrease of 40.9% from $2.157 million in 2025.
General and administrative expense, three months $1.398 million Company-reported increase of 27.3% from $1.135 million in 2025.
Net loss, three months $2.533 million Company-reported decrease of 24.2% from $3.262 million in 2025.
Research and development expense, nine months $4.868 million Company-reported increase of 28.9% from $3.765 million in 2025.
General and administrative expense, nine months $4.245 million Company-reported increase of 20.0% from $3.461 million in 2025.
Net loss, nine months $8.817 million Company-reported increase of 17.3% from $7.500 million in 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were SLXN’s third-quarter and nine-month 2026 results?

SLXN reported a $2.533 million net loss for the three months ended September 30, 2026, and an $8.817 million net loss for the nine months ended September 30, 2026. Cash and cash equivalents were $4.760 million at quarter-end.

How is SIL204 administered in SLXN’s Phase 2/3 trial?

SIL204 is administered through a dual-route regimen: EUS-guided intratumoral delivery to the primary tumor and subcutaneous injections designed to provide systemic exposure. The study evaluates SIL204 with standard-of-care chemotherapy versus chemotherapy alone in newly diagnosed, treatment-naïve patients with unresectable Stage 3 locally advanced pancreatic cancer and a confirmed KRAS mutation.

What financing transactions did SLXN report for the third quarter?

Silexion reported approximately $2.5 million in gross proceeds from an August public offering, approximately $0.84 million from a September warrant inducement transaction, and approximately $1.9 million in gross proceeds from ordinary-share sales under its at-the-market facility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002022416 00-0000000 0002022416 2026-11-16 2026-11-16 0002022416 us-gaap:CommonStockMember 2026-11-16 2026-11-16 0002022416 SLXN:WarrantsExercisableForOrdinarySharesMember 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 16, 2026 (November 13, 2026)

 

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-42253   N/A
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)       Identification No.)

 

12 Abba Hillel Road

Ramat-Gan, Israel

  5250606
(Address of principal executive offices)   (Zip Code)

 

+972-3-7564999

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $3.24 per share   SLXN   The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $372,600.00 per share   SLXNW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 13, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02.

 

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as may be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

99.1 Press Release, dated November 13, 2026, titled “Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update”

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SILEXION THERAPEUTICS CORP
   
Date: November 16, 2026 By: /s/ Ilan Hadar
  Name: Ilan Hadar
  Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

Silexion Therapeutics Reports Third Quarter 2026 Financial Results and

Provides Business Update

 

First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at

Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment

 

New translational data expanded SIL204’s profile, including a coordinated immune-sensitization

signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports

systemic administration

 

Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equity to

$3.0 million as of September 30, 2026

 

Grand Cayman, Cayman Islands, Nov. 13, 2026 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced financial results for the three-month and nine-month periods ended September 30, 2026, and provided a business update.

 

Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”

 

Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”

 

Recent Milestones & Business Highlights

 

First Patient Dosed in Phase 2/3 Clinical Trial of SIL204: On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (“LAPC”) at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), and on September 30, 2026, announced that the first patient worldwide had been dosed at TASMC. The prospective, randomized, controlled, multinational, open-label Phase 2/3 study is evaluating SIL204 in combination with standard-of-care chemotherapy, versus chemotherapy alone, in newly diagnosed, treatment-naïve patients with unresectable Stage 3 LAPC whose tumors harbor a confirmed KRAS mutation. SIL204 is administered via a dual-route regimen combining direct EUS-guided intratumoral delivery to the primary tumor with subcutaneous injections designed to provide systemic exposure. The study is structured as an initial safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of approximately 166 patients.

 

 

Clinical Site Expansion in Israel and Germany: In Israel, following the approval of the Israeli Ministry of Health, TASMC was activated as the trial’s first clinical site in July 2026, and the first patient was dosed there on September 30, 2026. Additional Israeli oncology centers, alongside leading academic medical institutions in Germany, are progressing through site activation and are expected to join the trial in the coming months.

 

Expanded Translational Profile of SIL204: In August 2026, Silexion reported preclinical findings showing statistically significant upregulation of FAS (CD95), an immune “death receptor,” and downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. Together with the MHC-I upregulation reported in May 2026, the findings support a coordinated immune-sensitization signature across three immune pathways and four KRAS mutations (G12D, G12V, G12C and G12R), reinforcing the scientific rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitor therapies. In September 2026, the Company reported that SIL204 uses naturally circulating lipoproteins to enter cancer cells and silence mutant KRAS without synthetic transfection reagents or artificial carriers, supporting the systemic administration of SIL204. Pharmacokinetic, cellular uptake kinetics and biodistribution studies are ongoing.

 

Financing Activities: During the third quarter, Silexion completed a registered public offering in August 2026 with gross proceeds of approximately $2.5 million and a warrant inducement transaction in September 2026 with gross proceeds of approximately $0.84 million, and continued sales of ordinary shares under its at-the-market facility for gross proceeds of approximately $1.9 million. Subsequent to quarter end, on November 10, 2026, the Company effected a 1-for-24 reverse share split.

 

Financial Results for the Three Months Ended September 30, 2026

 

Research and development (“R&D”) expenses for the three months ended September 30, 2026, were approximately $1.3 million, compared to approximately $2.2 million for the three months ended September 30, 2025, a decrease of 40.9%.

 

General and administrative (“G&A”) expenses for the three months ended September 30, 2026, were approximately $1.4 million, compared to approximately $1.1 million for the three months ended September 30, 2025, an increase of 27.3%.

 

Net loss for the three months ended September 30, 2026, was approximately $2.5 million, compared to approximately $3.3 million for the three months ended September 30, 2025, a decrease of 24.2%.

 

Financial Results for the Nine Months Ended September 30, 2026

 

R&D expenses for the nine months ended September 30, 2026, were approximately $4.9 million, compared to approximately $3.8 million for the nine months ended September 30, 2025, an increase of 28.9%. The increase related to the operational ramp-up for the Phase 2/3 clinical trial of SIL204.

 

G&A expenses for the nine months ended September 30, 2026, were approximately $4.2 million, compared to approximately $3.5 million for the nine months ended September 30, 2025, an increase of 20.0%.

 

Net loss for the nine months ended September 30, 2026, was approximately $8.8 million, compared to approximately $7.5 million for the nine months ended September 30, 2025, an increase of 17.3%. The increase was mainly due to higher R&D expenses related to the Phase 2/3 clinical trial of SIL204.

 

 

Balance Sheet Highlights

 

·As of September 30, 2026, Silexion had cash and cash equivalents of $4.8 million, compared to $6.0 million as of December 31, 2025, and $2.2 million as of June 30, 2026.

·Total shareholders’ equity was $3.0 million as of September 30, 2026, compared to $2.6 million as of December 31, 2025.

 

About Silexion Therapeutics

 

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication are forward-looking statements, including, for example, statements regarding the development of SIL204; the conduct, enrollment and timing of the ongoing Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, including enrollment of the safety run-in cohort and expansion into a randomized cohort; the timing of activation of additional clinical trial sites in Israel and Germany and the potential expansion of the trial into additional jurisdictions; the timing and results of ongoing translational, pharmacokinetic, cellular uptake and biodistribution studies, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic benefits, mutation coverage, mechanism of action and clinical utility of SIL204 across KRAS-driven cancers; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through its at-the-market facility, public and private offerings, warrant exercises, warrant inducement transactions and other financing arrangements; the outcome of litigation; and Silexion’s ability to restore and maintain compliance with Nasdaq continued listing requirements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204, and the risk that early observations may not be predictive of later results; (ii) Silexion’s ability to enroll and treat patients, and to complete the activation of additional clinical sites, on anticipated timelines; (iii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iv) the impact of the regulatory environment and compliance complexities; (v) whether Silexion is able to develop future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vii) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(e) to the Company’s unaudited condensed consolidated financial statements for the three-month and nine-month periods ended September 30, 2026; (viii) whether Silexion succeeds at maintaining its Nasdaq listing, including the determination of the Nasdaq hearings panel, compliance with the shareholders’ equity and minimum bid price requirements, and any potential increase to the market value of listed securities requirement; and (ix) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

 

Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com

 

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

 

 

SILEXION THERAPEUTICS CORP

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands, except share and per share data)

 

   September 30,   December 31, 
   2026   2025 
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents  $4,760   $5,991 
Restricted cash   28    27 
Prepaid expenses   1,221    570 
Other current assets   102    49 
TOTAL CURRENT ASSETS   6,111    6,637 
           
NON-CURRENT ASSETS:          
Restricted cash   61    57 
Long-term deposit and other non-current assets   320    84 
Property and equipment, net   21    25 
Operating lease right-of-use asset   314    412 
TOTAL NON-CURRENT ASSETS   716    578 
           
TOTAL ASSETS  $6,827   $7,215 

 

 

SILEXION THERAPEUTICS CORP

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

(U.S. dollars in thousands, except share and per share data)

 

   September 30,   December 31, 
   2026   2025 
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES:          
Trade payables  $1,244   $787 
Current maturities of operating lease liability   196    182 
Employee related obligations   460    879 
Other account payable   1,781    910 
Private warrants to purchase ordinary shares (including $* due to related party, as of September 30, 2026 and December 31, 2025)   *    * 
TOTAL CURRENT LIABILITIES   3,681    2,758 
           
NON-CURRENT LIABILITIES:          
Long-term operating lease liability   178    286 
Related Party Promissory Note   -    1,568 
TOTAL NON-CURRENT LIABILITIES  $178   $1,854 
TOTAL LIABILITIES  $3,859   $4,612 
           
SHAREHOLDERS’ EQUITY:          
Ordinary shares ($3.24 par value per share, 662,500 and 37,500 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 603,055 and 13,028 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively)   1,954    42 
Additional paid-in capital   64,997    57,727 
Accumulated deficit   (63,983)   (55,166)
TOTAL SHAREHOLDERS’ EQUITY  $2,968   $2,603 
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $6,827   $7,215 

 

All share amounts, and par value per share, reflect a 1-for-10 reverse share split effected on May 28, 2026, and a 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.

 

* Represents an amount less than $1 thousand.

 

 

SILEXION THERAPEUTICS CORP

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share and per share data)

 

   Nine months ended September 30,   Three months ended September 30, 
   2026   2025   2026   2025 
OPERATING EXPENSES:                    
Research and development (including $176 and $0 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $0 from related party for the three-month periods ended September 30, 2026 and 2025)  $4,868   $3,765   $1,286   $2,157 
General and administrative (including $298 and $96 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $16 and $38 from related party for the three-month periods ended September 30, 2026 and 2025, respectively)   4,245    3,461    1,398    1,135 
TOTAL OPERATING EXPENSES   9,113    7,226    2,684    3,292 
OPERATING LOSS   9,113    7,226    2,684    3,292 
Financial expenses (income), net (including $(307) and $203 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $(138) and $(26) from related party for the three-month periods ended September 30, 2026 and 2025, respectively)   (296)   271    (151)   (30)
LOSS BEFORE INCOME TAX  $8,817   $7,497   $2,533   $3,262 
INCOME TAX   *    3    *    - 
NET LOSS  $8,817   $7,500   $2,533   $3,262 
                     
LOSS PER SHARE, BASIC AND DILUTED  $115.56   $2,486.20   $13.70   $691.14 
                     
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE**   76,305    3,017    184,927    4,720 

 

* Represents an amount less than $1 thousand.

 

** All share and per share amounts reflect (for periods preceding the relevant reverse share split, on a retroactive basis) the 1-for-10 reverse share split effected on May 28, 2026 and the 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.

 

 

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading